Suggested remit: To appraise the clinical and cost effectiveness of selpercatinib within its marketing authorisation for treating RET fusion-positive advanced non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 3743

Project Team

Project lead Gavin Kenny

Email enquiries

Evidence Review Group / Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Consultees

Companies sponsors Eli Lilly (selpercatinib)
Others Department of Health and Social Care
  NHS England
  NHS Dorset CCG
  Welsh Government
Patient carer groups Roy Castle Lung Cancer Foundation
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel, vinorelbine) (confidentiality agreement not signed, not participating)
  Actavis UK (gemcitabine, paclitaxel, pemetrexed, vinorelbine) (confidentiality agreement not signed, not participating)
  Celgene (paclitaxel, nab-paclitaxel) (confidentiality agreement not signed, not participating)
  Consilient Health Ltd (carboplatin, vinorelbine) (confidentiality agreement not signed, not participating)
  Dr Reddy’s Laboratories (docetaxel, pemetrexed) (confidentiality agreement not signed, not participating)
  Fresenius Kabi (docetaxel, paclitaxel) (confidentiality agreement not signed, not participating)
  Fresenius Kabi Oncology (carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (confidentiality agreement not signed, not participating)
  Medac GmbH (vinorelbine) (confidentiality agreement not signed, not participating)
  Merck Sharp & Dohme (pembrolizumab)
  Pfizer (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel)
  Pierre Fabre (vinorelbine) (confidentiality agreement not signed, not participating)
  Roche (atezolizumab, bevacizumab, erlotinib)
  Sandoz (cisplatin) (confidentiality agreement not signed, not participating)
  Sanofi (docetaxel) (confidentiality agreement not signed, not participating)
  Seacross pharmaceuticals (docetaxel, paclitaxel) (confidentiality agreement not signed, not participating)
  Sun Pharma (carboplatin, gemcitabine) (confidentiality agreement not signed, not participating)
  Teva UK (carboplatin, cisplatin, docetaxel, paclitaxel) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
03 August 2020 Invitation to participate
14 May 2020 - 12 June 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 January 2020 In progress. Topic is in progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance